Full-Time

Senior Director of Regulatory Affairs

Inhalations

Updated on 9/3/2026

Deadline 3/13/27
Lupin Pharmaceuticals

Lupin Pharmaceuticals

10,001+ employees

Global pharmaceutical manufacturer and distributor

No salary listed

Coral Springs, FL, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)

Get referred to Lupin Pharmaceuticals

See people who can refer or advise you

Requirements
  • Drug development experience in chemistry, manufacturing, and controls and pharmacokinetics/pharmacodynamics clinical development is required.
  • A Master of Science or PhD in physical, pharmaceutical, biological, or other life sciences is required.
  • At least 10 years of hands-on regulatory experience, including 5 years in a management role, is required.
  • Eight to ten years of experience with a successful record of submissions and approvals of abbreviated new drug applications and new drug applications under section 505(b)(2) to the Food and Drug Administration is required.
  • Experience interacting with the Office of Generic Drugs and Office of New Drugs divisions of the Food and Drug Administration is required.
  • Experience with complex generic products such as US respiratory products and devices is required.
  • Excellent written and verbal communication and presentation skills are required.
  • Experience working with cross-functional, multinational teams is required.
  • Strong team management and team development skills are required.
  • Good oral and written English language skills are required.
Responsibilities
  • Establish regulatory direction and provide management support for the US development of complex inhalation products.
  • Guide and coordinate with Research and Development and HORA, review abbreviated new drug applications before or after submission, work with cross-functional teams to resolve outstanding issues, and ensure timely, high-quality submissions aimed at first-cycle approvals.
  • Build effective relationships with peers and staff from regional and functional regulatory bodies to develop US submission strategies and provide support as needed.
  • Engage in early product-development stages to ensure that abbreviated new drug applications for complex products contain sufficient information to support faster approval.
  • Implement 505(b)(2) strategies and submissions, maintain a strong communication strategy with the Food and Drug Administration, contribute expertise in the medical-device area, and understand the pharmacokinetics/pharmacodynamics strategy.
  • Support regulatory aspects of the company’s generic businesses.
  • Develop, coordinate, and execute regulatory strategies and guide personnel at all levels on appropriate approaches.
  • Coordinate and critically review documents for submission to US regulatory authorities.
  • Interact with the Food and Drug Administration, support regulatory filings, and ensure timely and high-quality submissions.
  • Establish productive working relationships with US regulatory authorities and provide guidance by addressing specific issues and information requests.
  • Conduct gap analyses and execute plans in a timely manner.
  • Establish and maintain engagement with cross-functional teams to complete tasks.
  • Understand and contribute scientifically to ongoing Research and Development projects.
  • Prepare information and related activities for meetings with drug regulatory agencies, conduct meetings, and prepare accurate meeting minutes.
  • Provide support for due-diligence activities associated with business development as required.
  • Supervise assigned regulatory staff and conduct periodic performance evaluations.
  • Perform other duties as assigned.
Lupin Pharmaceuticals

Lupin Pharmaceuticals

View

Lupin Limited develops and sells branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients across over 100 markets. It brings medicines to patients by designing formulations and APIs, manufacturing at 15 sites, and distributing through a global network, supported by 7 research centers. Its integrated model combines a broad product portfolio with dedicated manufacturing, diagnostics, digital health, and manufacturing services to serve multiple therapeutic areas. Its goal is to improve patient health outcomes by expanding access to high-quality medicines and strengthening its global research, manufacturing, and digital capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Mumbai, India

Founded

1968

Get referred to Lupin Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 FY27 sales rose 33.3% to INR 82,172 million, a company record.
  • Pitolisant, Sugammadex, Eribulin, and Revefenacin approvals broaden 2026 U.S. launch momentum.
  • August 2026 Tenpoint partnership expands ophthalmology revenues across Europe, the UK, and Switzerland.

What critics are saying

  • June 2026 prednisolone eye-drop recall hit 2.53 million bottles over foreign-substance contamination.
  • Ankleshwar received two FDA observations in March 2026, extending Lupin's compliance overhang.
  • Tolvaptan faces Apotex, Teva, and another entrant in September 2026, crushing pricing.

What makes Lupin Pharmaceuticals unique

  • Lupin is building a specialty care moat through VISUfarma and YUVEZZI in Europe.
  • Ranluspec became the only interchangeable ranibizumab biosimilar in U.S. vials and syringes.
  • Q1 FY27 record revenue came from complex launches, biosimilars, and 42% U.S. sales.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

15%

1 year growth

15%

2 year growth

15%
PR Newswire
Aug 20th, 2026
Lupin partners with Tenpoint to bring presbyopia eye drop YUVEZZI to Europe and UK

Lupin's subsidiary VISUfarma has secured exclusive rights to commercialise YUVEZZI, a once-daily presbyopia eye drop, across the EU, UK, Switzerland, Norway, and Iceland through a licensing agreement with Tenpoint Therapeutics' subsidiary Visus Therapeutics. Under the deal, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments plus tiered royalties based on net sales. YUVEZZI is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. The treatment addresses a condition affecting approximately 2 billion people globally. The partnership strengthens Lupin's vision care franchise following its acquisition of VISUfarma. Tenpoint is advancing US commercialisation and has submitted regulatory applications in the UK, with plans for additional markets worldwide.

PR Newswire
Aug 17th, 2026
Lupin receives US FDA approval for generic Pitolisant tablets

Lupin Limited has received final approval from the US Food and Drug Administration for its generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. The FDA approved Lupin's tablets as bioequivalent to Wakix for the indications in the approved labelling. Lupin is a Mumbai-based global pharmaceutical company that distributes products in over 100 markets. The company specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and six research centres globally, employing over 26,000 professionals.

PR Newswire
Jul 30th, 2026
Lupin launches generic Sugammadex injection in US after FDA approval

Lupin Limited has received US FDA approval and launched Sugammadex Injection in the United States. The product is available in two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials. Sugammadex Injection is bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged 2 years and older undergoing surgery. Lupin is a Mumbai-based pharmaceutical company with products distributed in over 100 markets. The firm specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and 7 research centres globally, employing over 26,000 professionals.

Multibagg AI
Jul 2nd, 2026
Lupin subsidiary to acquire 43.38% stake in Philippines' MPPI for up to $39.6M by May 2026

Lupin Ltd announced its subsidiary Nanomi B.V. will acquire a 43.38% stake in Multicare Pharmaceuticals Philippines Inc for up to $39.6 million in cash, with completion expected by end-May 2026. The deal involves purchasing 11,794,497 shares from existing shareholders to strengthen Lupin's presence in the Philippines. Separately, MPPI executed a buyback of 2,813,811 shares using retained earnings. As Nanomi did not participate, its holding automatically increased from 51% to 56.28%. MPPI reported turnover of PHP 2,096.60 million and net worth of PHP 1,265.50 million as of 31 March 2025. Lupin's shares fell 2.52% in early trade on 2 April following the announcement, trading at ₹2,216.20 on BSE.

PR Newswire
Jun 26th, 2026
Lupin receives tentative US FDA approval for generic Enzalutamide tablets

Lupin Limited has received tentative approval from the US FDA for its Enzalutamide Tablets in 40mg, 80mg, 120mg and 160mg strengths. The 40mg and 80mg versions were approved as bioequivalent to Astellas' Xtandi Tablets. Whilst Xtandi traditionally comes in 40mg and 80mg strengths, Lupin's tentatively approved 120mg and 160mg formulations will offer healthcare providers and patients additional dosing options. The Mumbai-based pharmaceutical company distributes products in over 100 markets globally. Lupin operates 15 manufacturing sites and seven research centres worldwide, employing over 24,000 professionals. The company specialises in branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapy areas including respiratory, cardiovascular and anti-diabetic treatments.